Enliven Therapeutics is a precision oncology startup based in Boulder, Colorado, that is developing small molecule therapies to extend and improve patient lives. The company’s focus is on clinically validated biological targets and industry-leading chemistry to address the limitations of existing cancer therapies. With their unique approach, Enliven Therapeutics aims to efﬁciently and effectively develop precision oncology therapeutics that enhance overall patient well-being.
Enliven Therapeutics uses a discovery process that combines clinically validated biological targets and industry-leading chemistry to develop precision oncology therapies. This approach allows the company to address the limitations of existing therapies and develop new drugs that have a higher chance of success. Enliven’s team has years of experience in the pharmaceutical industry and has a deep understanding of the clinical landscape of oncology. They use this knowledge to develop therapies that are more effective and have fewer side effects than traditional chemotherapy.
Small Molecule Therapies
Enliven Therapeutics is focused on developing small molecule therapies that can be taken orally. Small molecules are molecules that are small enough to be absorbed into cells and have a lower risk of side effects than traditional chemotherapy drugs. By developing small molecule therapies, Enliven Therapeutics is making cancer treatment more accessible and less invasive for patients.
Precision oncology is a growing field that aims to develop targeted therapies based on the individual characteristics of a patient’s cancer. Enliven Therapeutics is at the forefront of this field and is developing therapies that are tailored to the unique genetic makeup of each patient’s tumor. This approach allows for more effective treatment and fewer side effects.
Team and Leadership
Enliven Therapeutics was founded in July 2019 by Sam Kintz, MBA, Joe Lyssikatos, PhD, and Anish Patel, PharmD. The team has a deep understanding of the pharmaceutical industry and a passion for developing new cancer therapies. With their experience and expertise, Enliven’s leadership team is well-positioned to develop innovative and effective precision oncology therapies.
Enliven Therapeutics is a precision oncology startup that is focused on developing small molecule therapies to extend and improve patient lives. With their unique approach, the company aims to efﬁciently and effectively develop precision oncology therapeutics that enhance overall patient well-being. Enliven’s commitment to precision oncology and small molecule therapies has the potential to change the way we treat cancer and improve outcomes for patients worldwide.